메뉴 건너뛰기
Library Notice
Institutional Access
If you certify, you can access the articles for free.
Check out your institutions.
ex)Hankuk University, Nuri Motors
Log in Register Help KOR
Subject

An update on immunotherapy with PD-1 and PD-L1 blockade
Recommendations
Search

논문 기본 정보

Type
Academic journal
Author
KOH SUNG AE (영남대학교)
Journal
영남대학교 의과대학 Journal of Yeungnam Medical Science Journal of Yeungnam Medical Science 제38권 제4호 KCI Accredited Journals
Published
2021.10
Pages
308 - 317 (10page)
DOI
10.12701/yujm.2021.01312

Usage

cover
An update on immunotherapy with PD-1 and PD-L1 blockade
Ask AI
Recommendations
Search

Abstract· Keywords

Report Errors
Cancer is the leading cause of death and is on the rise worldwide. Until 2010, the development of targeted treatment was mainly focused on the growth mechanisms of cancer. Since then, drugs with mechanisms related to tumor immunity, especially immune checkpoint inhibitors, have proven effective, and most pharmaceutical companies are striving to develop related drugs. Programmed cell death-1 and programmed cell death ligand-1 inhibitors have shown great success in various cancer types. They showed durable and sustainable responses and were approved by the U.S. Food and Drug Administration. However, the response to inhibitors showed low percentages of cancer patients; 15% to 20%. Therefore, combination strategies with immunotherapy and conventional treatments were used to overcome the low response rate. Studies on combination therapy have typically reported improvements in the response rate and efficacy in several cancers, including non-small cell lung cancer, small cell lung cancer, breast cancer, and urogenital cancers. The combination of chemotherapy or targeted agents with immunotherapy is one of the leading pathways for cancer treatment.

Contents

No content found

References (64)

Add References

Recommendations

It is an article recommended by DBpia according to the article similarity. Check out the related articles!

Related Authors

Recently viewed articles

Comments(0)

0

Write first comments.